Home/Pipeline/KER-0193

KER-0193

Fragile X syndrome

PreclinicalActive

Key Facts

Indication

Fragile X syndrome

Phase

Preclinical

Status

Active

Company

Kaerus Bioscience

About Kaerus Bioscience

Kaerus Bioscience is a private, preclinical-stage biotech developing proprietary small molecule modulators of BK (KCa1.1) ion channels for rare neurodevelopmental disorders. Its lead program, KER-0193, targets the underlying neuronal hyperexcitability in Fragile X syndrome, with a parallel program for KCNMA1-linked channelopathies. The company is built on a specialized scientific platform and led by a team with deep drug development experience, aiming to address significant unmet needs in niche, genetically-defined patient populations.

View full company profile

Therapeutic Areas

Neurodevelopmental Disorders Rare Genetic Diseases

Other Fragile X syndrome Drugs

Drug	Company	Phase	Status
p70 S6 Kinase Inhibitor	Epigen Biosciences	Preclinical	Active
HLX-0206	Healx	AI Discovery	Active
ENT-3379	Enthorin Therapeutics	Phase 1	Active
AUT00206	Autifony Therapeutics	Clinical	Active
Fragile X Program	Sentinel Oncology	Preclinical	Active
Fragile X Syndrome Program	Purposeful	Discovery/Pre-clinical	Active
Fragile X Syndrome Trial	Science 37	Phase 3	Completed/Highlighted
DAYBUE® (trofinetide)	Neuren Pharmaceuticals	Phase 2	Completed
Fragile X Syndrome Test	Genomics BioSci & Tech	Clinical	Active
Xanamem (emestedastat)	Actinogen Medical	Phase 2	Active